ID: ALA2179119

Max Phase: Preclinical

Molecular Formula: C28H19FN4O

Molecular Weight: 446.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccnc4[nH]c(-c5ccccc5)cc34)[nH]2)cc1

Standard InChI:  InChI=1S/C28H19FN4O/c29-20-10-6-18(7-11-20)25-26(33-27(32-25)19-8-12-21(34)13-9-19)22-14-15-30-28-23(22)16-24(31-28)17-4-2-1-3-5-17/h1-16,34H,(H,30,31)(H,32,33)

Standard InChI Key:  HFDJAPMETZJFMI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 446.49

Molecular Weight (Monoisotopic): 446.1543

AlogP: 6.80

#Rotatable Bonds: 4

Polar Surface Area: 77.59

Molecular Species: NEUTRAL

HBA: 3

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.64

CX Basic pKa: 4.87

CX LogP: 6.13

CX LogD: 6.13

Aromatic Rings: 6

Heavy Atoms: 34

QED Weighted: 0.28

Np Likeness Score: -0.61

References

1. Selig R, Goettert M, Schattel V, Schollmeyer D, Albrecht W, Laufer S..  (2012)  A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors.,  55  (19): [PMID:22951114] [10.1021/jm300852w]

2. Juchum M, Günther M, Döring E, Sievers-Engler A, Lämmerhofer M, Laufer S..  (2017)  Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.,  60  (11): [PMID:28482151] [10.1021/acs.jmedchem.7b00178]

3. Shaikh M, Shinde Y, Pawara R, Noolvi M, Surana S, Ahmad I, Patel H..  (2022)  Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.,  65  (2.0): [PMID:34323489] [10.1021/acs.jmedchem.1c00876]

Source

Source(1):

• Scientific Literature